Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Qian Wu, De-Pei Wu, Suning Chen, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Sheng-Li Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Jianhong Fu, Xuefeng He

Blood (2023) 142 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2023-182749

Published: 2023

Journal Articles

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Jian Zhang, Baoquan Song, Yin Liu, Yanjun Wu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5950.

https://doi.org/10.1182/blood-2023-185770

Published: 2023

Journal Articles

Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Man Qiao, Xiaofei Yang, Xiebing Bao, Jihao Zhou, Han Zhu, Yanming Zhang, Tao You, Huiying Qiu, Ying Wang, Shengli Xue, Aining Sun, Yue Han, Xiao Ma, Xiaojin Wu, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 4922.

https://doi.org/10.1182/blood-2023-189348

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial

Huiying Qiu, Qiaomei He, Xi Sun, Ying Wang, Jiahua Niu, Jun Yang, Chongmei Huang, Kun Zhou, Yin Tong, Yu Cai, Baoxia Dong, Liping Wan, Xianmin Song

Blood (2023) 142 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2023-189174

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Jing Lu, Shengli Xue, Ying Wang, Hai-Ping Dai, Xuefeng He, Xiaohui Hu, Miao Miao, Huiying Qiu, Han Yue, Caixia Li, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 970.

https://doi.org/10.1182/blood-2023-181347

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Blood (2023) 142 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2023-184432

Published: 2023

Journal Articles

Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

Jing Lu, Ying Wang, Huiying Qiu, Xin Zhou, Xuzhang Lu, Miao Miao, Bin Gu, Xiaohui Hu, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 4243.

https://doi.org/10.1182/blood-2023-174831

Published: 2023

Journal Articles

Azacitidine Combined with Interferon α for Preemptive Treatment of AML/MDS after Allogeneic Peripheral Blood Stem Cell Transplantation：a Prospecitive Phase II Study

Chongmei Huang, Jun Yang, Yin Tong, Huiying Qiu, Kun Zhou, Xinxin Xia, Ying Zhang, Chang Shen, Liping Wan, Xianmin Song

Blood (2023) 142 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2023-179892

Published: 2023

Journal Articles

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Jian Zhang, Baoquan Song, Yin Liu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5947.

https://doi.org/10.1182/blood-2023-182665

Published: 2023

Journal Articles

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood (2023) 142 (15): 1323–1327.

https://doi.org/10.1182/blood.2023020102

Published: 2023

Includes: Supplemental data

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT

Huiying Qiu, Jiahua Niu, Xi Sun, Huajun Li, Juan Yang, Chongmei Huang, Yu CAI, Kun Zhou, Yin Tong, Liping Wan, Xianmin Song

Blood (2022) 140 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2022-162148

Published: 2022

Journal Articles

Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study

Xingying Li, Jun Yang, Liping Wan, Yu CAI, Kun Zhou, Chongmei Huang, Yin Tong, Huiying Qiu, Xianmin Song

Blood (2022) 140 (Supplement 1): 10471–10472.

https://doi.org/10.1182/blood-2022-164983

Published: 2022

Journal Articles

Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Zaihong Shen, Jun Yang, Yu CAI, Liping Wan, Chongmei Huang, Xiaowei Xu, Jiahua Niu, Xinxin Xia, Chang Shen, Huiying Qiu, Kun Zhou, Yin Tong, Xianmin Song

Blood (2022) 140 (Supplement 1): 4723.

https://doi.org/10.1182/blood-2022-163234

Published: 2022

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Jundan Xie, Xiaofei Yang, Xiebing Bao, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Xuefeng He, Xiaowen Tang, AiNing Sun, Hongchun Qiu, Shengli Xue, Ying Wang, Jianhong Fu, Huiying Qiu, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 1439–1440.

https://doi.org/10.1182/blood-2022-166384

Published: 2022

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

Azacitidine Combined with Interferon α for Preemptive Treatment of AML/MDS after Allogeneic Peripheral Blood Stem Cell Transplantation：a Prospecitive Phase II Study

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT

Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study

Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only